A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma
- 26 January 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Acta Oncologica
- Vol. 49 (1), 3-12
- https://doi.org/10.3109/02841860903150502
Abstract
Although some randomized controlled trials had compared the anti-CD20 monoclonal antibody rituximab plus chemotherapy (R-chemo) to chemotherapy alone for B-cell non-Hodgkin's lymphoma, the curative effects of R-chemo were still controversial. A systematic review and meta-analysis was performed to examine the efficacy of using R-chemo compared with the identical chemotherapy alone in the patients with B-cell non-Hodgkin's lymphoma. Medical databases and conference proceedings were searched for randomized controlled trials which compared R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed B-cell non-Hodgkin's lymphoma. Endpoints were overall survival, overall response, disease control, and adverse events. Twelve eligible trials were identified, reporting outcomes of 4 996 patients. Fixed-effects analysis showed overall survival to be superior for R-chemo-treated patients (relative risks [RR], 1.09; 95%confidence interval [CI], 1.06-1.12, p <0.00001). Superiority was also observed for the patients receiving R-chemo with respect to overall response (RR, 1.17; 95%CI, 1.10-1.25, p <0.00001), complete response (RR, 1.52; 95%CI, 1.27-1.82, p <0.00001), and disease control (RR, 1.36; 95%CI, 1.26-1.46, p <0.00001). R-chemo improved overall survival, overall response and disease control in patients with diffuse large B-cell lymphoma (RR, 1.11, 95%CI: 1.06-1.16, p 0.0001; RR, 1.09, 95%CI: 1.01-1.19, p = 0.03 and RR, 2.00, 95%CI: 1.59-2.53, p <0.00001, respectively) and follicular lymphoma (RR, 1.08, 95%CI: 1.04-1.12, p <0.0001; RR, 1.19, 95%CI: 1.07-1.33, p = 0.001 and RR, 2.58, 95%CI: 1.61-4.12, p 0.0001, respectively). Meanwhile, R-chemo improved overall response in patients with mantle cell lymphoma (RR, 1.22, 95%CI: 1.07-1.40, p = 0.004). R-chemo is superior to chemotherapy alone inKeywords
This publication has 27 references indexed in Scilit:
- Aiming at a Curative Strategy for Follicular LymphomaCA: A Cancer Journal for Clinicians, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysisJNCI Journal of the National Cancer Institute, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factorsEuropean Journal of Cancer, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Systematic Reviews: Identifying relevant studies for systematic reviewsBMJ, 1994